Japan Tissue Engineering (7774) · InitiativeAdvanced
Partnership with VC Cell Therapy to Commercialize iPS Cell-Based Regenerative Medicine Products
First written in FY2025. 1 of 2 entries say "Advanced", first in FY2026. Latest entry: FY2026.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Strategic partnerships and licensing in the iPS cell and regenerative medicine businessesA theme 2 companies write about · 0 as a headwind · 2 as a tailwind
1 other company's latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2026AdvancedAnnual report
「With respect to the bonds with stock acquisition rights issued by 株式会社VC Cell Therapy, we will underwrite all of the stock acquisition rights and the full amount of the bonds with stock acquisition rights issued by the company (capital alliance).」
Regarding the partnership with VC Cell Therapy to commercialize iPS cell-based regenerative medicine products, the capital alliance through the underwriting of bonds with stock acquisition rights in December 2024 has been disclosed as a contract. - FY2025First statedAnnual report
「We also entered into a capital and business alliance with 株式会社VC Cell Therapy to commercialize regenerative medicine products based on iPS cells, and began providing contracted services.」
We newly disclosed the capital and business alliance with VC Cell Therapy and the start of contracted services toward the commercialization of iPS cell-based regenerative medicine products.